Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
← catalyst calendarSponsored by Fulcrum Therapeutics (industry) · FULC — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
13actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-13 | actual | When the study began enrolling |
| Primary completion | 2026-06-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-01 | actual | The whole study's end, after follow-up |
| First posted | 2026-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sickle Cell Disease
Intervention
- Drug: Pociredir
Primary outcomes
what the primary-completion date above is the date OFPlasma concentration of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Maximum plasma concentration (Cmax) of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC(0-24)) of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC(0-tlast)) of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Area under the plasma concentration-time curve from time 0, extrapolated to infinity (AUC(0-inf)), of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Time to maximum plasma concentration (Tmax) of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Terminal disposition rate constant (λz) of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Terminal half-life (t1/2) of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Apparent volume of distribution during the terminal phase (Vz/F) of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Apparent clearance (CL/F) of pociredir under fasted and fed conditions
measured Day 1 through Day 4
Permalink · FULC's whole pipeline · Catalyst calendar · Every registered study · What changed